On September 21, InnoCare (a company invested by ZGC Development Group, SSE Code: 688428; HKSE Code: 09969) successfully went public on the Science and Technology Innovation Board of Shanghai Stock Exchange, becoming a biotech company listed on both A-shares and H-shares.

InnoCare plans to invest the raised funds in new drug research and development, drug R&D platform upgrade, marketing network construction, informatization and liquidity supplement.

China International Capital Corporation serves as the sponsor institution and co-lead underwriter of this listing on the SSE Science and Technology Innovation Board. Goldman Sachs Gao Hua Securities, JP Morgan Securities (China) and Yuekai Securities are also the co-lead underwriters of this issuance.